請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23209
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳基旺(Ji-Wang Chern) | |
dc.contributor.author | Chen-Jui Peng | en |
dc.contributor.author | 彭楨芮 | zh_TW |
dc.date.accessioned | 2021-06-08T04:47:35Z | - |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-15 | |
dc.identifier.citation | 1. http://www.who.int/healthinfo/morttables/en/.
2. Information retrieved from the Internet Homepages of the Department of Health, Taiwan, R. O. C (http://www.doh.gov.tw). 3. Zhang, J.; Yang, P. L.; Gray, N. S., Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer. 2009, 9, 28-39. 4. Sartore-Bianchi, A.; Ricotta, R.; Cerea, G.; Maugeri, M. R.; Siena, S., Rationale and clinical results of multi-target treatments in oncology. Int. J. Biol. Markers. 2007, 22, 77-87. 5. Petrelli, A.; Giordano, S., From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr. Med. Chem. 2008, 15, 422-432. 6. Ferrer-Soler, L.; Vazquez-Martin, A.; Brunet, J.; Menendez, J. A.; De Llorens, R.; Colomer, R., An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int. J. Mol. Med. 2007, 20, 3-10. 7. Schoffski, P.; Dumez, H.; Clement, P.; Hoeben, A.; Prenen, H.; Wolter, P.; Joniau, S.; Roskams, T.; Van Poppel, H., Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann. Oncol. 2006, 17, 1185-1196. 8. Lai, C. J.; Bao, R.; Tao, X.; Wang, J.; Atoyan, R.; Qu, H.; Wang, D. G.; Yin, L.; Samson, M.; Forrester, J.; Zifcak, B.; Xu, G. X.; DellaRocca, S.; Zhai, H. X.; Cai, X.; Munger, W. E.; Keegan, M.; Pepicelli, C. V.; Qian, C., CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res. 2010, 70, 3647-3656. 9. Cai, X.; Zhai, H. X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C. J.; Bao, R.; Qian, C., Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin- 6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem. 2010, 53, 2000-2009. 10. Piekarz, R. L.; Sackett, D. L.; Bates, S. E., Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer. J. 2007, 13, 30-39. 11. Marks, P. A., The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin. Invest. Drugs 2010, 19, 1049-1066. 12. Bolden, J. E.; Peart, M. J.; Johnstone, R. W., Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5, 769-784. 13. Minucci, S.; Pelicci, P. G., Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6, 38-51. 14. Yla-Herttuala, S.; Glass, C. K., Review focus on epigenetics and the histone code in vascular biology. Cardiovasc. Res. 2011, 90, 402-403. 15. Araki, Y., The role of histone modifications in differentiation and effector function of CD8 T cells: Update review including genome-wide analysis. Nihon Rinsho Meneki Gakkai Kaishi 2011, 34, 131-137. 16. Zhang, Y.; Feng, J.; Jia, Y.; Wang, X.; Zhang, L.; Liu, C.; Fang, H.; Xu, W., Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. J. Med. Chem. 2011, 54, 2823-2838. 17. Marson, C. M., Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med. Chem. 2009, 9, 661-692. 18. Carafa, V.; Nebbioso, A.; Altucci, L., Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat. Anticancer Drug Discov. 2011, 6, 131-145. 19. Huszar, D.; Theoclitou, M. E.; Skolnik, J.; Herbst, R., Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev. 2009, 28 , 197-208. 20. Zhang, Y.; Xu, W., Progress on kinesin spindle protein inhibitors as anti-cancer agents. Anticancer Agents Med. Chem. 2008, 8, 698-704. 21. Gschwind, A.; Fischer, O. M.; Ullrich, A., The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 2004, 4, 361-370. 22. Lee, C. B.; Socinski, M. A., Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. Rev. Recent Clin. Trials 2007, 2, 117-120. 23. Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, J., Vascular-specific growth factors and blood vessel formation. Nature 2000, 407, 242-248. 24. Ebos, J. M.; Lee, C. R.; Cruz-Munoz, W.; Bjarnason, G. A.; Christensen, J. G.; Kerbel, R. S., Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15, 232-239. 25. Sheth, P. R.; Basso, A.; Duca, J. S.; Lesburg, C. A.; Ogas, P.; Gray, K.; Nale, L.; Mannarino, A. F.; Prongay, A. J.; Le, H. V., Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein. Biochemistry 2009, 48, 11045-11055. 26. Khanwelkar, R. R.; Chen, G. S.; Wang, H. C.; Yu, C. W.; Huang, C. H.; Lee, O.; Chen, C. H.; Hwang, C. S.; Ko, C. H.; Chou, N. T.; Lin, M. W.; Wang, L. M.; Chen, Y. C.; Hseu, T. H.; Chang, C. N.; Hsu, H. C.; Lin, H. C.; Shih, Y. C.; Chou, S. H.; Tseng, H. W.; Liu, C. P.; Tu, C. M.; Hu, T. L.; Tsai, Y. J.; Chern, J. W., Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2- ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. 2010, 18, 4674-4686. 27. Yin, W.; Ma, Y.; Xu, J.; Zhao, Y., Microwave-assisted one-pot synthesis of 1-indanones from arenes and alpha,beta-unsaturated acyl chlorides. J. Org. Chem. 2006, 71, 4312-4315. 28. Lagerlund, O.; Larhed, M., Microwave-promoted aminocarbonylations of aryl chlorides using Mo (CO)6 as a solid carbon monoxide source. J. Comb. Chem. 2006, 8, 4-6. 29. Martinelli, J. R.; Watson, D. A.; Freckmann, D. M.; Barder, T. E.; Buchwald, S. L., Palladium-catalyzed carbonylation reactions of aryl bromides at atmospheric pressure: a general system based on Xantphos. J. Org. Chem. 2008, 73, 7102-7107. 30. Yi, C.; Hua, R., Efficient copper-free PdCl2 (PCy3) 2-catalyzed Sonogashira coupling of aryl chlorides with terminal alkynes. J. Org. Chem. 2006, 71 (6) , 2535-2537. 31. Littke, A. F.; Fu, G. C., Palladium-catalyzed coupling reactions of aryl chlorides. Angew. Chem. Int. Ed. Engl. 2002, 41, 4176-4211. 32. Svennebring, A.; Nilsson, P.; Larhed, M., Microwave-promoted and chelation-controlled double arylations of terminal olefinic carbon of vinyl ethers. J. Org. Chem. 2004, 69, 3345-3349. 33. Eriksson, L.; Winberg, K. J.; Claro, R. T.; Sjoberg, S., Palladium-catalyzed Heck reactions of styrene derivatives and 2-iodo-p-carborane. J. Org. Chem. 2003, 68, 3569-3573. 34. Svennebring, A.; Nilsson, P.; Larhed, M., Microwave-promoted and chelation-controlled double arylations of terminal olefinic carbon of vinyl ethers. J. Org. Chem. 2004, 69, 3345-3349. 35. Eriksson, L.; Winberg, K. J.; Claro, R. T.; Sjoberg, S., Palladium-catalyzed Heck reactions of styrene derivatives and 2-iodo-p-carborane. J. Org. Chem. 2003, 68, 3569-3573. 36. Al-Maksoud, W.; Mesnager, J.; Jaber, F.; Pinel, C.; Djakovitch, L., Synthesis of diethyl 2-(aryl) vinylphosphonates by the Heck reaction catalysed by well-defined palladium complexes. J. Organomet. Chem. 2009, 694, 3222-3231. 37. Wang, Z.; Zhang, Y.; Fu, H.; Jiang, Y.; Zhao, Y., Efficient intermolecular iron-catalyzed amidation of C-H bonds in the presence of N-bromosuccinimide. Org. Lett. 2008, 10, 1863-1866. 38. Jeffrey T. Finer; Gustave Bergnes; Bainian Feng; Whitney W. Smith.; John C. Chabala, Methods and composition utilizing quinazolinones. US 2008/0182864 A1. 39. Arnaiz, D.; Bryant, J.; C., Yuo-Ling; F., Richard; Hrvatin, P.; Islam, I.; Kochanny, M.; L., Wheeseong; Polokoff, M.; Y., Hongyi; Y., Shendong. Indolinone derivatives and their use in treating disease-states such as cancer. US 2005/0090541 A1. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23209 | - |
dc.description.abstract | 為了發展強效的癌症抑制劑,相較於以往的單靶抑制劑,多重靶向抑制劑現今被認為有更好的抗癌潛力,故本論文以多重靶向抑制劑為主要設計概念,分別將紡錘體驅動蛋白 (KSP) 抑制劑、酪胺酸激酶 (RTK) 抑制劑與組蛋白去乙醯化酶 (HDAC) 抑制劑確效結構醯基羥胺官能基,結合作為起始模板,設計併合成 KSP 與 HDAC 雙效抑制劑,N-(1-(3-苯甲基-7-(3-(羥胺基)-3-氧代丙-1-己烯)-4-羰基-3,4-二氫基-2-喹唑啉基)丙基)-N-(3-(二甲氨基)丙基)苯甲醯胺 (9)。目標化合物 9 是將醯基羥胺官能基建構於喹唑啉-4-酮衍生物,可由2-氨基-4-氯苯甲酸與正丁酰氯、亞磷酸三苯酯和苯甲胺經由一鍋法微波反應進行合環得到3-苯甲基-7-氯-2-丙基喹唑啉-4 (3H)-酮 (13),化合物13再溴化得2-(1-溴丙基)-7-氯-喹唑啉-4 (3H)-酮 (12) ,12與3-二甲氨基丙胺加熱迴流可得3-苯甲基-7-氯-2-(1-(3-(二甲氨基) 丙基氨基) 丙基) 喹唑啉-4 (3H)-酮 (11),化合物11在一氧化碳環境下與碘化苯進行耦合反應得N-[1-(3-苯甲基-7-氯-4-羰基-3,4-二氫喹唑啉-2-基)丙基]-N-[3-(二甲氨基)丙基]苯甲醯胺 (8),化合物8利用微波進行海克反應,得到乙基-3-(3-苯甲基-2-(1-(N-(3-(二甲氨基)丙基)苯甲酰胺基)丙基)-4-羰基-3,4-二氫-7-喹唑啉)丙烯酸酯 (10),並進一步水解得 3-(3-苯甲基-2-(1-(N-(3-(二甲氨基)丙基)苯甲酰胺基) 丙基)-4-羰基-3,4-二氫喹唑啉-7-基)丙烯酸 (19),化合物19 與 O-(四氫-2H-吡喃-2-基)羥基胺反應得N-(1-(3-苯甲基-4-羰基-7-(3-羰基-3-(四氫-2H-吡喃-2-氧基氨基)丙基-1-己烯基)-3,4-二氫-2-喹唑啉基)丙基)-N-(3-(二甲氨基)丙基)苯甲醯胺 (20),最後以三氟醋酸切除保護官能基後以Sephadex LH-20進行分離純化目標化合物 9。在合成目標化合物 9 的同時,並以微波發展合成先導化合物 8,有效縮短總反應時間及提升合成總產率36倍。 RTK 與 HDAC 雙效抑制劑3-芳香基吲哚衍生物 24 是將醯基羥胺官能基建構於 3-芳香基吲哚衍生物,由6-氯吲哚酮為起始物依序經醇醛縮合反應、海克反應和官能基轉換而得,推測此類化合物結構呈現平面構形造成溶解度差,也許會導致活性測試上的偏差,故尚未進行後續活性測試。將合成出的唑啉-4-酮衍生物對胃癌細胞株 (AGS) 和腸癌細胞株 (HCT116) 進行體外癌細胞毒性測試,結果顯示目標化合物 9 具有癌細胞抑制活性 (AGS IC50 = 3.58 μM; HCT116 IC50 = 0.46 μM) ,雖然在 HDAC未如預期有抑制活性,但此類唑啉-4-酮衍生物作為癌症抑制劑具有發展潛力並值得繼續探索。 | zh_TW |
dc.description.abstract | In order to explore more potent anti-cancer agent, multi-target inhibitors were regarded more potential than single target. A combination of the hydroxamic acid moiety in histone deacetylases (HDAC) inhibitors at active site with functional moieties of kinesin spindle protein (KSP) or receptor tyrosine kinase (RTK) inhibitors functional moieties were designed and synthesized based on this hypothesis. A potential multi-target inhibitor of KSP and HDAC, N-(1-(3-benzyl-7- (3-(hydroxyamino)-3-oxoprop-1-enyl)-4-oxo-3,4-dihydroquinazolin-2-yl)propyl)-N-(3-(dimethylamino)propyl)benzamide (9) was designed as preliminary compound with quinazoline-4-one scaffold bearing hydroxamic acid moiety. Compound 9 was synthesized through several steps including cyclization of 2-amino-4- chlorobenzoic acid with n-butyryl chloride and benzylamine via microwave-assisted one-pot reaction to provide 3-benzyl-7-chloro-2-propylquinazolin-4(3H)-one (13). Bromination of 13 provided 2-(1-Bromopropyl)-7-chloroquinazolin-4(3H)-one (12). Amination of 12 with 3-dimethylaminopropylamine provided 3-benzyl- 7-chloro-2-(1-(3-(dimethylamino)propylamino)propyl)quinazolin-4-(3H)-one (11). Compound 11 was coupled with iodobenzene under carbon monoxide to provide N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl]-N-[3-(dimethylamino)propyl]benzamide (8). Compound 8 was reacted with ethyl acrylate through microwave-assisted Heck reaction provide 3,4-dihydroquinazolin-7-yl)acrylate (10). Compound 10 was hydrolysis to provide 3-(3-benzyl-2-(1-(N-(3-(dimethylamino)propyl)benzamido)propyl)-4-oxo-3,4-dihydroquinazolin-7-yl) acrylic acid (19). Compound 19 was protected by O-(tetrahydro-2H-pyran-2-yl) hydroxylamine to provide N-(1-(3-benzyl-4-oxo-7-(3-oxo-3-(tetrahydro-2H-pyran- 2-yloxyamino)prop-1-enyl)-3,4-dihydroquinazolin-2-yl)propyl)-N-(3-(dimethylamino)propyl)benzamide (20). Finally, protecting group was cleaveged by trifluoroacetic acid and purified by Sephadex LH-20 to get compound 9. In the synthesis of target compound 9, reaction time was shorten and total yield was improvement in 36-folds comparing to original approach through microwave-assistance synthesis of KSP lead compound 8. 3-arylindole derivatives 24 were designed as RTK and HDAC dual inhibitors by combinating of hydroxamic acid with 3-arylindole scaffold and synthesized from 6-chlorooxindole via 3 steps. However, the solubilities of these series of compounds were poor, and led some difficulties in biological assays. Quinazoline-4-one derivatives were subjected to anti-proliferative activity against two human tumor cell lines (AGS and HCT116) by SRB assay. Compound 9 shows micromolar range inhibitory activity to these two cell line (AGS IC50 = 3.58 μM; HCT116 IC50 = 0.46 μM). Although 9 didn't demonstrate HDAC inhibition, the research suggested that quinazoline-4-one derivatives might serve as good lead compound for the development of anticancer agents. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T04:47:35Z (GMT). No. of bitstreams: 1 ntu-100-R98423016-1.pdf: 20905342 bytes, checksum: 85e470e5c1f0a1dad02898e82b3c9145 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 中文摘要 VIII
Abstract X 第一章 緒論 1 1.1癌症 1 1.2雙重目標腫瘤抑制劑 2 1.3組蛋白去乙醯化酶 5 1.4 紡錘體驅動蛋白 9 1.5酪胺酸激酶 13 第二章 實驗設計 15 2.1紡錘體驅動蛋白與組蛋白去乙醯化酶雙效抑制劑之設計 15 2.2酪胺酸激酶與組蛋白去乙醯化酶雙效抑制劑之設計 18 第三章 結果與討論 19 3.1喹唑啉-4-酮衍生物之合成 19 3.2 3-芳香基吲哚衍生物之合成 31 3.3生物活性測試 37 第四章 結論 42 第五章 實驗部分 44 5.1實驗儀器和檢驗方法 44 5.2實驗藥品與溶劑 44 5.3 生物活性測試步驟 45 5.4合成步驟 46 第六章 參考文獻 69 第七章 附錄 73 | |
dc.language.iso | zh-TW | |
dc.title | 設計與合成喹唑啉-4-酮和3-芳香基吲哚衍生物作為潛能腫瘤抑制劑 | zh_TW |
dc.title | Design and Synthesis of Quinazoline-4-one and 3-Arylindole Derivatives as Potential Anti-cancer Agents | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王光昭(Kuang-Chao Wang),顧記華(Jih-Hwa Guh),忻凌偉(Ling-Wei Hsin),陳香惠(Shia-huy Chen) | |
dc.subject.keyword | 癌症,喹,唑啉,醯基羥胺,多靶, | zh_TW |
dc.subject.keyword | cancer,quinazoline,hydroxamic acid,multi-target, | en |
dc.relation.page | 90 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2011-08-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 20.42 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。